DOAC use reduces risk of CKD progression in patients with AF compared with VKA use

Written By : Dr Kartikeya Kohli |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2023-02-25T09:30:20+05:30 | Updated On 25 Feb 2023 2:55 PM IST

A recent study by Marco Trevisan and team found that Direct oral anticoagulant (DOAC) use is associated with a lower risk of chronic kidney disease (CKD) progression, acute kidney injury (AKI), and major bleeding compared to vitamin K antagonists (VKA) use in patients with nonvalvular atrial fibrillation (AF), with no significant difference in the risk of death or the composite of stroke and systemic embolism. The findings were published in American Journal of Kidney Diseases.

Direct oral anticoagulants have become the preferred choice over vitamin K antagonists for stroke prevention in patients with nonvalvular AF due to their lower risk of bleeding complications. This study aimed to investigate the impact of DOACs and VKAs on kidney outcomes in patients with nonvalvular AF.

The retrospective cohort study involved 32,699 Swedish patients with nonvalvular AF between 2011-2018. Patients were initiated on either DOAC or VKA treatment, and the primary outcomes were CKD progression and AKI. The secondary outcomes were death, major bleeding, and the composite of stroke and systemic embolism. Propensity score weighted Cox regression was used to balance 50 baseline confounders.

The study found that DOAC use was associated with a lower risk of CKD progression, AKI, and major bleeding compared to VKA use. The adjusted hazard ratios (HRs) for DOAC versus VKA were 0.87 for CKD progression and 0.88 for AKI. However, there was no significant difference in the risk of death or the composite of stroke and systemic embolism between the two groups. The results were consistent across subgroups of age, sex, and baseline eGFR, and when patients were at high risk for thromboembolic events.

Reference:

Trevisan, M., Hjemdahl, P., Clase, C. M., de Jong, Y., Evans, M., Bellocco, R., Fu, E. L., & Carrero, J. J. (2023). Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants. In American Journal of Kidney Diseases (Vol. 81, Issue 3, pp. 307-317.e1). Elsevier BV. https://doi.org/10.1053/j.ajkd.2022.07.017

American Journal of Kidney DiseasesNonvalvular Atrial Fibrillationdirect oral anticoagulants

Source : American Journal of Kidney Diseases

Dr Kartikeya Kohli

Dr Kartikeya Kohli is an Internal Medicine Consultant at Sitaram Bhartia Hospital in Delhi with super speciality training in Nephrology. He has worked with various eminent hospitals like Indraprastha Apollo Hospital, Sir Gangaram Hospital. He holds an MBBS from Kasturba Medical College Manipal, DNB Internal Medicine, Post Graduate Diploma in Clinical Research and Business Development, Fellow DNB Nephrology, MRCP and ECFMG Certification. He has been closely associated with India Medical Association South Delhi Branch and Delhi Medical Association and has been organising continuing medical education programs on their behalf from time to time. Further he has been contributing medical articles for their newsletters as well. He is also associated with electronic media and TV for conduction and presentation of health programs. He has been associated with Medical Dialogues for last 3 years and contributing articles on regular basis.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751